Centenara Labs is a technology company.
Centenara Labs has raised $75.0M across 1 funding round.
Centenara Labs has raised $75.0M in total across 1 funding round.
Centenara Labs is a clinical-stage biotechnology company developing therapies that target the hallmarks of aging to expand human healthspan and address geriatric diseases like cancer, fibrosis, sarcopenia, and retinal degeneration.[1][3][5] Operating as a "hub and spoke" model, it builds a diversified pipeline through internal development and portfolio companies such as Endogena Therapeutics (clinical-stage for eye diseases via stem cell activation) and RejuverSen (pre-clinical senolytics for cancer and fibrosis), serving the healthcare and pharmaceutical sectors amid rising global aging populations.[1][2][5] With $101.13M raised in Series B funding as of 2023, it focuses on high-unmet-need areas like triple-negative breast cancer, IPF/CKD fibrosis, telomere restoration, and vascular cognitive decline, aiming to reduce healthcare burdens through breakthrough therapeutics.[3][5]
Centenara Labs, formerly Rejuveron Life Sciences, was founded in 2019 and is headquartered in Zurich, Switzerland.[3][4] It emerged from a vision to translate aging research into drugs, backed by entrepreneur Christian Angermayer of Apeiron Investment Group, who brings 20+ years in life sciences and deep tech, alongside Etienne (25+ years in healthcare fundraising) and scientific leaders like a University of Paris Cité professor known for mitochondrial research in cell death.[4] Pivotal early traction included a $75M Series B and convertible loan in September 2023, rebranding to Centenara Labs, and advancing assets like Endogena's EA-2353 for retinitis pigmentosa into clinical stages while building pre-clinical programs in senolytics and telomeres.[1][3][6]
Centenara Labs rides the longevity biotech wave, targeting aging's root hallmarks (e.g., senescence, telomere attrition) as global populations age, straining healthcare with diseases like IPF, CKD, and sarcopenia.[1][5] Timing aligns with advances in senolytics and regenerative medicine, fueled by market forces like increased life expectancy and investor interest in healthspan extension (e.g., post-2023 funding surge).[3] It influences the ecosystem by de-risking early discoveries into clinical assets, partnering with specialists like Endogena, and pioneering multi-indication therapies that could expand to broader age-related conditions, accelerating industry shift from symptom treatment to reversal.[2][4]
Centenara Labs is poised for milestone catalysts, including RejuverSen's 2025 IND entry for breast cancer and fibrosis programs, alongside telomere and vascular advances potentially yielding first-in-class approvals.[1][5] Rising AI-driven drug discovery and longevity funding trends will amplify its momentum, evolving it from pipeline builder to multi-asset leader in healthspan therapies. As aging demographics intensify, its hub model could redefine biotech efficiency, delivering on the promise of healthier, longer lives that hooked us from the start.[2][3]
Centenara Labs has raised $75.0M in total across 1 funding round.
Centenara Labs's investors include Define Ventures, Dragoneer Investment Group, Mubadala, Ayman AlAbdallah.
Centenara Labs has raised $75.0M across 1 funding round. Most recently, it raised $75.0M Series B in September 2023.
| Date | Round | Lead Investors | Other Investors |
|---|---|---|---|
| Sep 1, 2023 | $75.0M Series B | Define Ventures, Dragoneer Investment Group, Mubadala, Ayman AlAbdallah |